

Resource Summary Report

Generated by [RRID](#) on Aug 11, 2026

CD31-PE, human

RRID:AB_2660561

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-098-173, RRID:AB_2660561

Antibody Information

URL: http://antibodyregistry.org/AB_2660561

Proper Citation: Miltenyi Biotec Cat# 130-098-173, RRID:AB_2660561

Target Antigen: CD31

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 3-2018; Target Distribution basophils, endothelial cells, fibroblasts, granulocytes, leukocytes, lymphocytes, macrophages, monocytes, neutrophils, NK cells, osteoclasts, plasma cells, platelets, T cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-119-142. (RRID:AB_2733806).

Antibody Name: CD31-PE, human

Description: This monoclonal targets CD31

Target Organism: non-human primate, human

Clone ID: AC128

Antibody ID: AB_2660561

Vendor: Miltenyi Biotec

Catalog Number: 130-098-173

Record Creation Time: 20250820T003622+0000

Record Last Update: 20250820T084250+0000

Ratings and Alerts

No rating or validation information has been found for CD31-PE, human.

Warning: Discontinued: 2021

Discontinued: 3-2018; Target Distribution basophils, endothelial cells, fibroblasts, granulocytes, leukocytes, lymphocytes, macrophages, monocytes, neutrophils, NK cells, osteoclasts, plasma cells, platelets, T cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-119-142. (RRID:AB_2733806).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Pagano E, et al. (2023) TRPM8 indicates poor prognosis in colorectal cancer patients and its pharmacological targeting reduces tumour growth in mice by inhibiting Wnt/??-catenin signalling. British journal of pharmacology, 180(2), 235.

Holloway EM, et al. (2020) Differentiation of Human Intestinal Organoids with Endogenous Vascular Endothelial Cells. Developmental cell, 54(4), 516.